» Articles » PMID: 38448761

Impact of a Multidisciplinary Management Team on Clinical Outcome in ICU Patients Affected by Gram-negative Bloodstream Infections: a Pre-post Quasi-experimental Study

Abstract

Background: Bloodstream infections (BSIs) by Gram-negative pathogens play a major role in intensive care patients, both in terms of prevalence and severity, especially if multi-drug resistant pathogens are involved. Early appropriate antibiotic therapy is therefore a cornerstone in the management of these patients, and growing evidence shows that implementation of a multidisciplinary team may improve patients' outcomes. Our aim was to evaluate the clinical and microbiological impact of the application of a multidisciplinary team on critically ill patients.

Methods: Pre-post study enrolling critically ill patients with Gram negative bloodstream infection in intensive care unit. In the pre-intervention phase (from January until December 2018) patients were managed with infectious disease consultation on demand, in the post-intervention phase (from January until December 2022) patients were managed with a daily evaluation by a multidisciplinary team composed of intensivist, infectious disease physician, clinical pharmacologist and microbiologist.

Results: Overall, 135 patients were enrolled during the study period, of them 67 (49.6%) in the pre-intervention phase and 68 (50.4%) in the post-intervention phase. Median age was 67 (58-75) years, sex male was 31.9%. Septic shock, the need for continuous renal replacement therapy and mechanical ventilation at BSI onset were similar in both groups, no difference of multidrug-resistant organisms (MDRO) prevalence was observed. In the post-phase, empirical administration of carbapenems decreased significantly (40.3% vs. 62.7%, p = 0.02) with an increase of appropriate empirical therapy (86.9% vs. 55.2%, p < 0.001) and a decrease of overall antibiotic treatment (12 vs. 16 days, p < 0.001). Despite no differences in delta SOFA and all-cause 30-day mortality, a significant decrease in microbiological failure (10.3% vs. 29.9%, p = 0.005) and a new-onset 30-day MDRO colonization (8.3% vs. 36.6%, p < 0.001) in the post-phase was reported. At multivariable analysis adjusted for main covariates, the institution of a multidisciplinary management team (MMT) was found to be protective both for new MDRO colonization [OR 0.17, 95%CI(0.05-0.67)] and microbiological failure [OR 0.37, 95%CI (0.14-0.98)].

Conclusions: The institution of a MMT allowed for an optimization of antimicrobial treatments, reflecting to a significant decrease in new MDRO colonization and microbiological failure among critically ill patients.

Citing Articles

Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review.

Gatti M, Pea F Front Antibiot. 2025; 3():1426753.

PMID: 39816245 PMC: 11732092. DOI: 10.3389/frabi.2024.1426753.


Gram-Negative Bloodstream Infections in a Medical Intensive Care Unit: Epidemiology, Antibiotic Susceptibilities, and Risk Factors for in-Hospital Death.

Long G, Peng P, Li Y Infect Drug Resist. 2024; 17:5087-5096.

PMID: 39584180 PMC: 11585302. DOI: 10.2147/IDR.S493267.


Characteristics of Oral spp. and Evolution of Plasmid-Mediated Carbapenem Resistance in Bacteremia Patients with Hematological Malignancies.

Li H, Talanaite D, Pan Z, Wang Z, Wang S, Wang H Infect Drug Resist. 2024; 17:4753-4761.

PMID: 39494231 PMC: 11531724. DOI: 10.2147/IDR.S478362.


Association Between Infectious Diseases Consultation and Mortality in Hospitalized Patients With Gram-negative Bloodstream Infection: A Retrospective Population-wide Cohort Study.

Ong S, Luo J, Fridman D, Lee S, Johnstone J, Schwartz K Clin Infect Dis. 2024; 79(4):855-863.

PMID: 38758977 PMC: 11478582. DOI: 10.1093/cid/ciae282.

References
1.
Sumi C, Heffernan A, Lipman J, Roberts J, Sime F . What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clin Pharmacokinet. 2019; 58(11):1407-1443. DOI: 10.1007/s40262-019-00791-z. View

2.
Alshaer M, Maranchick N, Alexander K, Manigaba K, Shoulders B, Felton T . Beta-lactam target attainment and associated outcomes in patients with bloodstream infections. Int J Antimicrob Agents. 2023; 61(3):106727. DOI: 10.1016/j.ijantimicag.2023.106727. View

3.
Falcone M, Tiseo G, Carbonara S, Marino A, Di Caprio G, Carretta A . Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network). Clin Infect Dis. 2023; 76(12):2059-2069. DOI: 10.1093/cid/ciad100. View

4.
Hassoun-Kheir N, Hussein K, Karram M, Saffuri M, Badaan S, Peleg S . Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study. Clin Microbiol Infect. 2023; 29(5):629-634. DOI: 10.1016/j.cmi.2023.01.005. View

5.
Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M . Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management. Clin Infect Dis. 2017; 66(8):1204-1210. DOI: 10.1093/cid/cix991. View